SB-649,915

From WikiMD's WELLNESSPEDIA

SB-649,915 is a drug that was developed by GlaxoSmithKline for the treatment of depression. It acts as a potent and selective 5-HT1A receptor antagonist, and has been researched for its potential antidepressant effects.

History[edit]

SB-649,915 was developed by the pharmaceutical company GlaxoSmithKline. It was designed to act as a potent and selective antagonist for the 5-HT1A receptor, a type of serotonin receptor that is often targeted in the treatment of depression and other mood disorders.

Mechanism of Action[edit]

SB-649,915 works by blocking the action of the 5-HT1A receptor. This receptor is one of several that are activated by serotonin, a neurotransmitter that is involved in the regulation of mood, appetite, and sleep. By blocking the action of this receptor, SB-649,915 may help to increase the availability of serotonin in the brain, which could potentially improve symptoms of depression.

Clinical Trials[edit]

While SB-649,915 has been studied in clinical trials, it has not yet been approved for use in the treatment of depression. The results of these trials have not been publicly disclosed, so it is not currently known how effective this drug may be in treating depression or what side effects it may cause.

See Also[edit]

References[edit]


Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.